Este sitio web utiliza cookies propias para ofrecer un mejor servicio. Si continúa navegando consideramos que acepta su uso. Encontrará más información en nuestra Política de Cookies.
OK | Más informaciónSolicitudes publicadas en los últimos 150 días / Applications published in the last 150 days
NºPublicación: US2022244262A1 04/08/2022
Solicitante:
MAYO FOUND MEDICAL EDUCATION & RES [US]
Resumen de: US2022244262A1
This document relates to materials and methods involved in assessing inflammatory bowel disease patients at risk for developing cancer. For example, materials and methods for monitoring colorectal cancer risk in ulcerative colitis patients are provided.
NºPublicación: US2022233686A1 28/07/2022
Solicitante:
PSOMAGEN INC [US]
Resumen de: US2022233686A1
The present disclosure relates to pharmaceutical compounds and compositions and methods for treating an allergy and Crohn's disease. Methods for treating an allergy can include (a) predicting potential epitopes based proteomes of microbiome and that of an allergen, (b) filtering the potential epitopes obtained in step a) to result in a list of epitopes; and (c) reengineering the list of epitopes obtained in step b) to result in the new epitope. Methods for treating Crohn's disease can include (a), identifying one or more binding regions of an HLA class II protein and/or hemagglutinin to I2 superantigen; (b) determining a first peptide sequence corresponding to the one or more binding regions, and (c) producing a peptide inhibitor having a second peptide sequence that is a mutation of the first peptide sequence, wherein the second peptide sequence has a stronger binding affinity to the I2 superantigen than the first peptide sequence.
NºPublicación: AU2020407659A1 28/07/2022
Solicitante:
ICAHN SCHOOL MED MOUNT SINAI
Resumen de: AU2020407659A1
The present invention provides methods of diagnosing, treating, and monitoring the progression of inflammatory bowel disease in a subject, including, for example, by monitoring ROR
NºPublicación: WO2022158882A1 28/07/2022
Solicitante:
CATHOLIC UNIV KOREA IND ACADEMIC COOPERATION FOUNDATION [KR]
Resumen de: WO2022158882A1
It was identified that intestinal organoids derived human blood and endocytes of the present invention expressed the intestinal differentiation markers CGA, CDX2, LYZ, ECAD, KLF5, MUC2, Ki67, VIL, LGR5, SOX9, VIM, and SMA, thereby effectively reflecting intestinal conditions and can assay intestinal protection and intestinal secretions according to treatment with microbiomes. In addition, the (Bifidobacterium microbiome RAPO of the present invention was identified to upregulate the expression of IL-10 and REG3A and induce the expression of lysozyme, E-cadherin, and CGA and the proliferation of intestinal crypts in the intestinal organoids. Furthermore, intestinal organoids of the present invention were examined for responses to treatment with homologous PBMC to identify the reactivity of transplant rejection. In addition, an inflammatory bowel disease simulated avatar model of the present invention was identified to allow for effectively engrafting human blood immune cells thereto and induce the development of inflammatory bowel disease and the injury of intestinal tissues, thereby effectively reflecting diseased conditions of patients. Also, it was identified that injection of PBMC from patients with inflammatory bowel disease advanced the inflammatory bowel diseases, compared to injection of PBMC from normal persons and treatment with candidate materials could palliate the inflammatory bowel diseases, whereby therapeutic agents customized for patients can be screened.
NºPublicación: EP4032906A1 27/07/2022
Solicitante:
BOEHRINGER INGELHEIM INT [DE]
Resumen de: EP4032906A1
This invention generally relates to methods for the treatment of IL-23 related diseases, in particular inflammatory diseases, such as Crohn's Disease, utilizing anti-IL-23A antibodies.
NºPublicación: EP4032586A1 27/07/2022
Solicitante:
REBIOTIX INC [US]
Resumen de: EP4032586A1
This document discusses, among other things, receiving a plurality of donor fecal samples from a plurality of donors and storing and indexing each respective donor fecal samples using at least one characteristic of the respective donor fecal sample. In an example, the donor fecal sample can be screened and processed for subsequent use in fecal bacteriotherapy to displace pathogenic or undesired organisms in the digestive track of a patient with healthy or desirable gut micriobiota.
NºPublicación: US2022227848A1 21/07/2022
Solicitante:
NORDIC BIOSCIENCE AS [DK]
Resumen de: US2022227848A1
The present invention provides monoclonal antibodies that target collagen type XXIII, and to immunoassays and kits employing the antibodies for detecting and quantifying the epitope. The invention also provides a method for identifying and monitoring subjects with inflammatory bowel disease.
NºPublicación: AU2022204649A1 21/07/2022
Solicitante:
TAKEDA PHARMACEUTICALS CO [JP]
Resumen de: AU2022204649A1
DIAGNOSIS AND TREATMENT OF AUTOIMMUNE DISEASES Methods, kits and compositions for diagnosing and treating autoimmune diseases such as rheumatoid arthritis, Crohn's disease, and ulcerative colitis.
NºPublicación: JP2022106732A 20/07/2022
Solicitante:
ジェネンテック,インコーポレイテッド
Resumen de: WO2014160753A1
Methods of assessing or monitoring the effect, efficacy, responsiveness to treatment, and/or determining a dose or dosing regimen of therapeutic agents, such as integrin beta7 antagonists, for the treatment of gastrointestinal inflammatory disorders are provided. In certain aspects, methods of using integrin beta7 subunit-containing receptor occupancy by the integrin beta7 antagonist on colonic lymphocytes as an indicator ("biomarker") of the effect, efficacy, or responsiveness to treatment, and/or as a means to determine dosing or dosing regimens of therapeutic agents such as beta7 integrin antagonists for the treatment of gastrointestinal inflammatory disorders are provided. In certain aspects, methods of assessing the effect, efficacy, or responsiveness to beta7 integrin antagonist treatment by measuring gene expression levels of one or more integrin receptor ligands, lymphocyte genes, cytokine genes, or the number of alphaE-positive cells in intestinal crypt epithelium are provided.
NºPublicación: EP4029516A1 20/07/2022
Solicitante:
UNIV ANTWERPEN [BE]
Resumen de: EP4029516A1
The present invention relates to the field of mucins and isoforms thereof, more in particular for use in the diagnosis, monitoring, prevention and/or treatment of a disease characterized by barrier dysfunction, such as but not limited to a gastrointestinal disorder (e.g. Inflammatory Bowel Disease (IBD), Irritable Bowel Syndrome (IBS), cancer, gastro-intestinal infections, obesitas, non-alcoholic fatty liver disease (NAFLD)), neurodegenerative disorders, respiratory infections,... more in particular coronaviral infections In a specific embodiment, said mucins and/or isoforms thereof are selected from the list comprising: MUC16, MUC21, MUC2, MUC4, MUC5AC, MUC5B, MUC13, and MUC1 and isoforms thereof
NºPublicación: US2022221471A1 14/07/2022
Solicitante:
KUNMING INST ZOOLOGY CAS [CN]
Resumen de: US2022221471A1
The present disclosure provides use of a reagent for detecting an expression level of transferrin in the preparation of a diagnostic reagent or kit for a disease caused by imbalance of intestinal immune tolerance, and belongs to the technical field of medical molecular biology. In the present disclosure, the severity of intestinal inflammatory diseases is diagnosed according to the transferrin level, achieving the objective of the early diagnosis of the disease caused by imbalance of intestinal immune tolerance. In the present disclosure, the transferrin is used as a marker for imbalance of intestinal immune tolerance, featuring high specificity and sensitivity, and simple detection procedure.
NºPublicación: US2022221445A1 14/07/2022
Solicitante:
THE BOARD OF TRUSTEESOFTHELELANDSTANFORDJUNIORUNIVERSITY [US]
Resumen de: US2022221445A1
Air-liquid interface organoid cultures are initiated from human small intestine biopsy tissue comprising both the synintestinal epithelium and native intestinal immune cells, without reconstitution, which may be obtained from an individual pre-disposed or suffering from celiac disease. The organoid cultures exhibit T cell activation in response to in vitro gluten challenge and provide tools for a novel diagnostic method for celiac disease. Diagnosis may comprise the addition of immunogenic gluten-derived peptides into the organoid cultures, and assessing hallmarks of active celiac disease, including without limitation: 1) gliadin-presentation, resulting T-cell responses, such as 2) expansion and 3) activation, 4) epithelial-cell death and consequent 5) increased proliferative epithelial cell responses to gliadin. Celiac patients, either in GRD or GFD, test positive for these tests. In other embodiments the organoids are used to test responses to candidate therapeutic agents, assessing reduction of gliadin-dependent (1) T cell activation or expansion, or (2) organoid epithelial cell death.
NºPublicación: US2022220448A1 14/07/2022
Solicitante:
CLEVELAND CLINIC FOUND [US]
Resumen de: US2022220448A1
Provided herein are compositions, systems, kits, and methods that employ a colitic induced human colitic organoid (iHCO) that has both an epithelial compartment and mesenchymal compartment, and provides at least one feature (e.g., leaky epithelial barrier) of IBD patient tissue (e.g., ulcerative colitis or Crohn's disease tissue). In certain embodiments, such iHCO's are employed in vitro or in vivo to screen candidate IBD treating compounds (e.g., to determine effectiveness for a particular patient who was the source of the original colonic fibroblasts used to generate the iHCO).
NºPublicación: AU2020414720A1 14/07/2022
Solicitante:
AARDVARK THERAPEUTICS INC
Resumen de: AU2020414720A1
There is disclosed a method for treatment, prevention, and/or slowing of progression for various chronic inflammatory disorder groups including (1) type 2 diabetes group (metabolic syndrome (MET), obesity, hyperglycemia); (2) ARDS (acute respiratory distress syndrome); (3) chronic autoimmune inflammatory disorders (rheumatoid arthritis (RA), lupus, and psoriasis); (4) inflammatory bowel diseases (IBD), such as Crohn's disease and ulcerative colitis; (5) metabolome-mediated diseases (atherosclerosis, hypertension, and congestive heart failure); and (6) hyperphagia disorders such as Prader-Willi Syndrome and other monogenic and syndromic obesity disorders including leptin pathway deficiencies, each comprising administering orally a pharmaceutical composition comprising a denatonium salt. The present disclosure is based on readouts from a series of studies tracking clusters of biomarkers levels to track mediators of inflammatory disorders and mediators of gutsignaling hormones in response to orally administered denatonium salts.
NºPublicación: WO2022149342A1 14/07/2022
Solicitante:
PANASONIC HOLDINGS CORP [JP]
Resumen de: WO2022149342A1
This excrement determination device obtains image data of excrement captured by a camera for imaging the interior of the bowl of a toilet, calculates a G/R value and a B/R value on the basis of the R (red) value, the G (green) value and the B (blue) value included in the image data, determines whether or not said image data includes an image of a bowel movement, urination and/or bleeding on the basis of the G/R value and the B/R value, and outputs the determination results.
NºPublicación: JP2022532381A 14/07/2022
Solicitante:
プロサイセデクスインコーポレイティド
Resumen de: WO2020232262A1
Assay methods for detecting the presence or amount of VCAM-1 or calprotectin in a sample using fluorescence resonance energy transfer (FRET).
NºPublicación: CN114732899A 12/07/2022
Solicitante:
辉瑞公司
Resumen de: WO2016110806A2
The present invention provides a method for the treatment of a patient comprising administering to the patient an initial dose of between about 1 mg and about 150 mg of a MAdCAM antagonist antibody. Biomarkers for assessing a patient's response to anti-MAdCAM treatment are also provided.
NºPublicación: AU2020403007A1 07/07/2022
Solicitante:
UNIV WASHINGTON
Resumen de: AU2020403007A1
Methods for treating, selecting a treatment, and monitoring a treatment for an inflammatory bowel disease in a patient in need are disclosed. Treatments include administering an antifungal compound. The method for selecting and monitoring a treatment includes detecting a biomarker indicative of an amount of the fungus Debaryomyces hansenii within the sample. The treatment is administered if the biomarker is above a threshold level and the biomarker may be monitored before and during treatment. Biomarkers include abundance of fungal DNA in the patient's gut microbiota and anti-fungal antibodies in the blood of the patient.
NºPublicación: US2022214357A1 07/07/2022
Solicitante:
UNIV LIMERICK [IE]
Resumen de: US2022214357A1
The Applicant has discovered a cytokine profile that can accurately distinguish between ulcerative colitis (UC) and Crohn's disease (CD) in a subject having, or having symptoms of, inflammatory bowel disease (IBD). The profile of ulcerative colitis is increased IL-10 levels (compared with a reference IL-10 level, and decreased IL-23 levels (compared with a reference IL-23 level). The cytokine profile can be detected at a protein or genomic level, and is generally determined from a peripheral blood sample (i.e. a blood fraction such as serum, plasma, or blood cells such as peripheral blood mononuclear cells). Distinguishing between UC and CD in a subject with IBD allows a clinician prescribe a suitable therapeutic regime for the subject using a non-invasive blood test, and avoiding the need for scoping or tissue biopsy, which are undesirable for the subject. The cytokine profile can also be used to monitor a therapeutic regime for effectiveness.
NºPublicación: EP4023162A2 06/07/2022
Solicitante:
HANUMAT CO LTD [JP]
EA PHARMA CO LTD [JP]
Resumen de: EP4023162A2
The present invention provides a method for determining the likelihood of colorectal cancer development in a human ulcerative colitis patient, the method including: a measurement step of measuring methylation rates of one or more CpG sites present in specific differentially methylated regions in DNA recovered from a biological sample collected from the human ulcerative colitis patient; and a determination step of determining the likelihood of colorectal cancer development in the human ulcerative colitis patient based on average methylation rates of the differentially methylated regions which are calculated based on the methylation rates measured in the measurement step and a preset reference value or a preset multivariate discrimination expression, in which the reference value is a value for identifying a cancerous ulcerative colitis patient and a non-cancerous ulcerative colitis patient, which is set for the methylation rate of each differentially methylated region, and the multivariate discrimination expression includes, as variables, average methylation rates of one or more differentially methylated regions among the specific differentially methylated regions.
NºPublicación: US2022205999A1 30/06/2022
Solicitante:
UNIV COLORADO STATE RES FOUND [US]
Resumen de: US2022205999A1
The present disclosure relates to methods for diagnosing and treating inflammatory bowel disease (IBD) in companion animals.
NºPublicación: WO2022139580A1 30/06/2022
Solicitante:
FERRING BV [NL]
Resumen de: WO2022139580A1
The present invention relates to an sgp130 protein, exemplified by olamkicept, for use 5 in treating individuals for inflammatory bowel diseases (IBD). In particular, the invention provides a panel of gene expression biomarkers that predict response in patients with inflammatory bowel disease after a single administration of as sgp130 protein, such as olamkicept.
NºPublicación: WO2022140283A1 30/06/2022
Solicitante:
CEDARS SINAI MEDICAL CENTER [US]
Resumen de: WO2022140283A1
Disclosed herein are methods, kits and compositions for treating an inflammatory disease or condition, or fibrosis in a subject that has been determined to have increased fold-change in Tumor necrosis factor (TNF)-like cytokine 1A (TL1A) expression based, at least partially, on a presence of a combination of genotypes detected in a sample obtained from the subject. In some embodiments, the combination of genotypes is significantly associated with the increased fold-change in TL1A, and in some cases, may also be predictive of severe forms of the inflammatory disease or condition. In some embodiments, the inflammatory disease or condition is an inflammatory bowel disease, such as Crohn's disease or ulcerative colitis.
NºPublicación: EP4017880A1 29/06/2022
Solicitante:
ASTRAZENECA COLLABORATION VENTURES LLC [US]
Resumen de: WO2021035129A1
The disclosure relates to products and methods for treating Crohn's disease. The products relate to antibodies that inhibit native human IL-23, but do not inhibit IL-12. The disclosure also relates to methods of selecting a subject amenable to IL-23 inhibition therapy to treat Crohn's disease as well as methods of identifying a patient sub-population amenable to such treatment.
Nº publicación: JP2022095664A 28/06/2022
Solicitante:
シーダーズ―シナイメディカルセンター
Resumen de: WO2017161342A1
The present invention describes methods of diagnosing inflammatory bowel disease, including but not limited to Crohn's Disease (CD), Ulcerative Colitis (UC), and/or Medically Refractive Ulcerative Colitis (MR-UC), using RNASET2, TL1A and/or IFN-ϒ. The invention further provides a process for patient identification and/or stratification.